User profiles for Gonzalo Carreño-Tarragona

Gonzalo Carreno-Tarragona

MD, PhD, Haematology and Haemotherapy Department, Hospital Universitario 12 de …
Verified email at salud.madrid.org
Cited by 1127

[HTML][HTML] Magnitude and dynamics of the T-cell response to SARS-CoV-2 infection at both individual and population levels

…, K Dobbs, R Laguna-Goya, G Carreño-Tarragona… - MedRxiv, 2020 - ncbi.nlm.nih.gov
T cells are involved in the early identification and clearance of viral infections and also
support the development of antibodies by B cells. This central role for T cells makes them a …

[HTML][HTML] A large-scale database of T-cell receptor beta (TCRβ) sequences and binding associations from natural and synthetic exposure to SARS-CoV-2

…, OM Delmonte, K Dobbs, G Carreño-Tarragona… - Research …, 2020 - ncbi.nlm.nih.gov
We describe the establishment and current content of the ImmuneCODE™ database, which
includes hundreds of millions of T-cell Receptor (TCR) sequences from over 1,400 subjects …

[HTML][HTML] NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma

…, L Fernández, G Carreño-Tarragona… - Blood Cancer …, 2021 - nature.com
CAR-T-cell therapy against MM currently shows promising results, but usually with serious
toxicities. CAR-NK cells may exert less toxicity when redirected against resistant myeloma …

Clinical course and risk factors for mortality from COVID‐19 in patients with haematological malignancies

…, C Cuellar, G CarreñoTarragona… - European Journal of …, 2020 - Wiley Online Library
Background The impact of coronavirus disease 2019 (COVID‐19) in haematological patients
(HP) has not been comprehensively reported. Methods We analysed 39 patients with SARS…

[HTML][HTML] High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

…, KSQ Cervantes, MS Serrano, G Carreno-Tarragona… - Leukemia, 2021 - nature.com
We report the clinical presentation and risk factors for survival in 175 patients with
myeloproliferative neoplasms (MPN) and COVID-19, diagnosed between February and June 2020. …

[HTML][HTML] Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia

…, Y Hoade, WJ Tapper, G Carreno-Tarragona… - Leukemia, 2019 - nature.com
Determining the underlying cause of persistent eosinophilia is important for effective clinical
management but remains a diagnostic challenge in many cases. We identified STAT5B …

CNL and aCML should be considered as a single entity based on molecular profiles and outcomes

G Carreño-Tarragona, A Álvarez-Larrán… - Blood …, 2023 - ashpublications.org
Chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) are rare
myeloid disorders that are challenging with regard to diagnosis and clinical management. …

Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance …

…, B Xicoy, MJ Ramírez, G CarreñoTarragona… - Cancer, 2022 - Wiley Online Library
Background Ruxolitinib is approved for patients with polycythemia vera (PV) who are
resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease‐progression …

[HTML][HTML] Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission …

…, I Rapado, ML Morales, G Carreño-Tarragona… - …, 2021 - ncbi.nlm.nih.gov
In cases of treatment failure in acute myeloid leukemia (AML), the utility of mutational profiling
in primary refractoriness and relapse is not established. We undertook a perspective study …

Optical nanoparticles for cardiovascular imaging

…, N Fernandez, G CarreñoTarragona… - Advanced Optical …, 2018 - Wiley Online Library
The current status of the use of optical nanoparticles for imaging of the cardiovascular
system is reviewed in detail. The different types of optical (luminescent, photoacoustic, and …